N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
University of California, San Francisco
University of California, San Francisco
University of California, San Francisco
City of Hope Medical Center
Mayo Clinic
Masonic Cancer Center, University of Minnesota
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Mayo Clinic
Fred Hutchinson Cancer Center
Mayo Clinic
Mayo Clinic
Northwestern University
City of Hope Medical Center
Fred Hutchinson Cancer Center
Northwestern University
Fred Hutchinson Cancer Center
Northwestern University
University of California, San Francisco
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
University of Washington
Vanderbilt-Ingram Cancer Center